Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday

Corvus Pharmaceuticals (CRVS) is expected to report its Q4 2025 earnings before the market opens on Thursday, March 12th, with analysts projecting a loss of ($0.14) per share. Several analysts have recently increased their price targets for CRVS, with the average target now at $31.80 and a “Moderate Buy” consensus rating. The stock’s performance shows recent trading at $15.80, a wide 52-week range, and significant institutional interest.